Interview with the CEO and Chairman: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
Richard M. Glickman, LL.D., presently serves as the CEO and Chairman of the board of Aurinia Pharmaceuticals Inc. In addition to being a Founder of the company, he previously served as the Interim Executive Chairman of Aurinia for the period September 20, 2013, to February 28, 2014, and as Acting Interim CEO for the period October 22, 2013, to November 5, 2013. Dr. Glickman was a Co-Founder, Chairman and CEO of Aspreva Pharmaceuticals, playing an integral role in the development and establishment of CellCept, or mycophenolate mofetil — MMF — as the current standard of care for lupus nephritis. Aspreva Pharmaceuticals was acquired by Swiss pharmaceutical company Galenica for nearly $1 billion in 2008. He currently serves as founding Chairman of Essa Pharmaceuticals Inc., Chairman of the board of Engene Corporation and a Director of Cardiome Pharma (NASDAQ:CRME). Dr. Glickman is also a Partner at Lumira Capital, one of Canada’s most successful health-care-focused venture capital firms. He has served on numerous biotechnology and community boards, and he has served as a member of the federal government’s National Biotechnology Advisory Committee, a Director of the Canadian Genetic Disease Network, Chairman of Life Sciences B.C. and a member of the British Columbia Innovation Council. Dr. Glickman has received numerous awards, including the Ernst and Young Entrepreneur of the Year, both British Columbia and Canada’s Top 40 under 40 awards, the BC Lifesciences Leadership Award and the Corporate Leadership Award from the Lupus Foundation of America. Profile
TWST: What is Aurinia Pharmaceuticals?
Dr. Glickman: Aurinia is a biopharma company focused specifically on the treatment of nephritis and lupus nephritis. We have